Cullinan Therapeutics CGEM Stock
Cullinan Therapeutics Price Chart
Cullinan Therapeutics CGEM Financial and Trading Overview
| Cullinan Therapeutics stock price | 12.36 USD |
| Previous Close | 11.77 USD |
| Open | 12.07 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 11.92 - 12.92 USD |
| 52 Week Range | 7.78 - 15.89 USD |
| Volume | 529.9K USD |
| Avg. Volume | 275.57K USD |
| Market Cap | 499.88M USD |
| Beta (5Y Monthly) | 0.090277 |
| PE Ratio (TTM) | 10.672268 |
| EPS (TTM) | -3.32 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29 USD |
CGEM Valuation Measures
| Enterprise Value | 79.15M USD |
| Trailing P/E | 10.672268 |
| Forward P/E | -2.8222222 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.02884 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.494 |
Trading Information
Cullinan Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.090277 |
| 52-Week Change | 4.09% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.89 USD |
| 52 Week Low | 7.78 USD |
| 50-Day Moving Average | 10.36 USD |
| 200-Day Moving Average | 11.41 USD |
CGEM Share Statistics
| Avg. Volume (3 month) | 275.57K USD |
| Avg. Daily Volume (10-Days) | 438.54K USD |
| Shares Outstanding | 39.36M |
| Float | 19.57M |
| Short Ratio | 8.13 |
| % Held by Insiders | 11.86% |
| % Held by Institutions | 81.93% |
| Shares Short | 2.27M |
| Short % of Float | 7.29% |
| Short % of Shares Outstanding | 5.75% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.028% |
| Return on Equity (ttm) | 14.13% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -160084000 USD |
| Net Income Avi to Common (ttm) | 65.35M USD |
| Diluted EPS (ttm) | 1.19 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 390.7M USD |
| Total Cash Per Share (mrq) | 9.93 USD |
| Total Debt (mrq) | 6.57M USD |
| Total Debt/Equity (mrq) | 1.35 USD |
| Current Ratio (mrq) | 15.247 |
| Book Value Per Share (mrq) | 12.344 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -155752992 USD |
| Levered Free Cash Flow (ttm) | -66675500 USD |
Profile of Cullinan Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | One Main Street |
| ZIP | 02142 |
| Phone | 617 410 4650 |
| Website | https://www.cullinanoncology.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 62 |
Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Q&A For Cullinan Therapeutics Stock
What is a current CGEM stock price?
Cullinan Therapeutics CGEM stock price today per share is 12.36 USD.
How to purchase Cullinan Therapeutics stock?
You can buy CGEM shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cullinan Therapeutics?
The stock symbol or ticker of Cullinan Therapeutics is CGEM.
Which industry does the Cullinan Therapeutics company belong to?
The Cullinan Therapeutics industry is Biotechnology.
How many shares does Cullinan Therapeutics have in circulation?
The max supply of Cullinan Therapeutics shares is 59.08M.
What is Cullinan Therapeutics Price to Earnings Ratio (PE Ratio)?
Cullinan Therapeutics PE Ratio is now.
What was Cullinan Therapeutics earnings per share over the trailing 12 months (TTM)?
Cullinan Therapeutics EPS is -3.32 USD over the trailing 12 months.
Which sector does the Cullinan Therapeutics company belong to?
The Cullinan Therapeutics sector is Healthcare.
Cullinan Therapeutics CGEM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23576.49 USD — |
+0.13
|
6.38B USD — | 23449.73 USD — | 23616.46 USD — | — - | 6.38B USD — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 11551.81 USD — |
+0.13
|
— — | 11490.06 USD — | 11571.03 USD — | — - | — — |
| US Tech Biotechnology NBI | 5622.4 USD — |
-1.73
|
— — | 5619.21 USD — | 5739.5 USD — | — - | — — |
| US Tech Health Care IXHC | 1174.64 USD — |
-1.32
|
— — | 1173.89 USD — | 1194.31 USD — | — - | — — |
- {{ link.label }} {{link}}